Hi @Martin37,
that’s undoubtedly the situation now IMO, especially as regards the Lonza Tuas international facility inspection. Given MSB’s confirmation that new assay(s) are involved, an inspection - but logistically might be broken into ‘general’ and ‘release assay specific’ - would probably need to be post-settlement with OTAT of the content of the additional assay(s).
CEO Itescu advised the market some time ago that this inspection sits on the critical path to approval.
As I recall (without checking) he expressed the dependency as ‘determining’ the timing.
BLA resubmission for children with SR-aGVHD, page-4
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.018(1.60%) |
Mkt cap ! $1.230B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.09 | $1.07 | $1.010M | 934.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 100704 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 27513 | 6 |
View Market Depth
| Last trade - 10.55am 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |